S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Oil tanker breaks down in Egypt's Suez Canal, briefly disrupting traffic in the global waterway
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
With oil prices slumping, OPEC+ producers weigh more production cuts
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Oil tanker breaks down in Egypt's Suez Canal, briefly disrupting traffic in the global waterway
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
With oil prices slumping, OPEC+ producers weigh more production cuts
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Oil tanker breaks down in Egypt's Suez Canal, briefly disrupting traffic in the global waterway
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
With oil prices slumping, OPEC+ producers weigh more production cuts
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Oil tanker breaks down in Egypt's Suez Canal, briefly disrupting traffic in the global waterway
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
With oil prices slumping, OPEC+ producers weigh more production cuts
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
NASDAQ:ARCT

Arcturus Therapeutics (ARCT) Stock Forecast, Price & News

$26.88
-0.19 (-0.70%)
(As of 06/2/2023 ET)
Compare
Today's Range
$26.45
$27.66
50-Day Range
$15.50
$32.36
52-Week Range
$11.70
$33.80
Volume
307,594 shs
Average Volume
418,086 shs
Market Capitalization
$713.93 million
P/E Ratio
6.64
Dividend Yield
N/A
Price Target
$32.25

Arcturus Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.30 Rating Score
Upside/​Downside
20.0% Upside
$32.25 Price Target
Short Interest
Bearish
13.76% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.46mentions of Arcturus Therapeutics in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$1.05 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.62) to ($6.25) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.81 out of 5 stars

Medical Sector

712th out of 983 stocks

Pharmaceutical Preparations Industry

354th out of 486 stocks


ARCT stock logo

About Arcturus Therapeutics (NASDAQ:ARCT) Stock

Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Its products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.

Receive ARCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arcturus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ARCT Stock News Headlines

“Amazon Loophole” could hand you $28,544 in “royalty” payouts
Thanks to a little-known IRS loophole… Regular Americans can collect up to $28,544 (or more) in payouts from what Brad Thomas calls the “Amazon secret royalty program…” See how to collect the next payout before the strict cutoff deadline.
Arcturus Therapeutics (NASDAQ: ARCT)
Chinook Therapeutics (KDNY) Gets a Buy from Piper Sandler
Protagonist Therapeutics (PTGX) Gets a Buy from Piper Sandler
15 A.I. Trading Opportunities a Day
Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.
See More Headlines

ARCT Price History

ARCT Company Calendar

Last Earnings
3/28/2023
Today
6/04/2023
Next Earnings (Estimated)
8/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ARCT
Fax
N/A
Employees
177
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$32.25
High Stock Price Forecast
$51.00
Low Stock Price Forecast
$14.00
Forecasted Upside/Downside
+20.0%
Consensus Rating
Hold
Rating Score (0-4)
2.30
Research Coverage
10 Analysts

Profitability

Net Income
$9.35 million
Pretax Margin
40.09%

Debt

Sales & Book Value

Annual Sales
$206 million
Cash Flow
$0.41 per share
Book Value
$12.40 per share

Miscellaneous

Free Float
23,322,000
Market Cap
$713.93 million
Optionable
Optionable
Beta
2.60

Key Executives

  • Joseph E. Payne
    President, Chief Executive Officer & Director
  • Padmanabh Chivukula
    Secretary, Chief Operating & Scientific Officer
  • Andrew H. Sassine
    Chief Financial Officer & Director
  • Dushyant B. Varshney
    Chief Technology Office & Executive VP
  • Kevin T. Skol
    Chief Business Officer













ARCT Stock - Frequently Asked Questions

Should I buy or sell Arcturus Therapeutics stock right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Arcturus Therapeutics in the last year. There are currently 3 sell ratings, 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ARCT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ARCT, but not buy additional shares or sell existing shares.
View ARCT analyst ratings
or view top-rated stocks.

What is Arcturus Therapeutics' stock price forecast for 2023?

10 brokers have issued twelve-month target prices for Arcturus Therapeutics' shares. Their ARCT share price forecasts range from $14.00 to $51.00. On average, they predict the company's share price to reach $32.25 in the next year. This suggests a possible upside of 20.0% from the stock's current price.
View analysts price targets for ARCT
or view top-rated stocks among Wall Street analysts.

How have ARCT shares performed in 2023?

Arcturus Therapeutics' stock was trading at $16.96 at the beginning of 2023. Since then, ARCT shares have increased by 58.5% and is now trading at $26.88.
View the best growth stocks for 2023 here
.

Are investors shorting Arcturus Therapeutics?

Arcturus Therapeutics saw a increase in short interest in May. As of May 15th, there was short interest totaling 3,320,000 shares, an increase of 5.7% from the April 30th total of 3,140,000 shares. Based on an average daily volume of 521,600 shares, the short-interest ratio is presently 6.4 days. Currently, 13.8% of the shares of the stock are sold short.
View Arcturus Therapeutics' Short Interest
.

When is Arcturus Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our ARCT earnings forecast
.

How were Arcturus Therapeutics' earnings last quarter?

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) issued its quarterly earnings data on Tuesday, March, 28th. The biotechnology company reported $4.33 EPS for the quarter, beating the consensus estimate of ($1.86) by $6.19. The biotechnology company had revenue of $160.29 million for the quarter, compared to the consensus estimate of $134.54 million. Arcturus Therapeutics had a net margin of 39.59% and a trailing twelve-month return on equity of 36.88%.

What is Joe Payne's approval rating as Arcturus Therapeutics' CEO?

11 employees have rated Arcturus Therapeutics Chief Executive Officer Joe Payne on Glassdoor.com. Joe Payne has an approval rating of 90% among the company's employees. 70.0% of employees surveyed would recommend working at Arcturus Therapeutics to a friend.

What other stocks do shareholders of Arcturus Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arcturus Therapeutics investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Novavax (NVAX), Dynavax Technologies (DVAX), Pfizer (PFE), OPKO Health (OPK), NVIDIA (NVDA), Abbott Laboratories (ABT), CRISPR Therapeutics (CRSP) and

What is Arcturus Therapeutics' stock symbol?

Arcturus Therapeutics trades on the NASDAQ under the ticker symbol "ARCT."

Who are Arcturus Therapeutics' major shareholders?

Arcturus Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Federated Hermes Inc. (17.99%), State Street Corp (8.43%), ARK Investment Management LLC (7.48%), BlackRock Inc. (6.76%), Sumitomo Mitsui Trust Holdings Inc. (5.35%) and Nikko Asset Management Americas Inc. (5.35%). Insiders that own company stock include Andy Sassine, Joseph E Payne, Keith C Kummerfeld, Magda Marquet, Pad Chivukula and Ultragenyx Pharmaceutical Inc.
View institutional ownership trends
.

How do I buy shares of Arcturus Therapeutics?

Shares of ARCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Arcturus Therapeutics' stock price today?

One share of ARCT stock can currently be purchased for approximately $26.88.

How much money does Arcturus Therapeutics make?

Arcturus Therapeutics (NASDAQ:ARCT) has a market capitalization of $713.93 million and generates $206 million in revenue each year. The biotechnology company earns $9.35 million in net income (profit) each year or $4.05 on an earnings per share basis.

How many employees does Arcturus Therapeutics have?

The company employs 177 workers across the globe.

How can I contact Arcturus Therapeutics?

Arcturus Therapeutics' mailing address is 10628 SCIENCE CENTER DRIVE SUITE 200, SAN DIEGO CA, 92121. The official website for the company is www.arcturusrx.com. The biotechnology company can be reached via phone at (858) 900-2660 or via email at ir@arcturusrx.com.

This page (NASDAQ:ARCT) was last updated on 6/4/2023 by MarketBeat.com Staff

My Account -